Skip to main content

Prior asthma exacerbations predict future risk

Hospitalised patient_woman

The risk for moderate or severe asthma exacerbations is primarily predicted by the occurrence of prior corresponding exacerbations, shows research.


HBV suppresses hepatic innate immune response

DNA background

The host hepatic innate immune response is downregulated in untreated patients with chronic hepatitis B virus infection, shows a gene expression analysis.


Larotrectinib ‘potential standard of care’ for adult, pediatric TRK fusion tumors

David Hyman

Preliminary findings for larotrectinib suggest that the agent may offer an effective tumor type-agnostic treatment for adults and children presenting with tropomyosin receptor kinase fusions.


Support for adding tofacitinib to methotrexate in patients with RA


Results of the ORAL Strategy trial suggest that tofacitinib given in combination with methotrexate, but not alone, is noninferior to adalimumab plus methotrexate for the treatment of patients with rheumatoid arthritis and an inadequate response to methotrexate.

Headlines from across medwireNews

23-06-2017 | Breast cancer | News | Article

Adjuvant capecitabine improves prognosis in high-risk breast cancer

Patients with residual invasive disease after standard neoadjuvant chemotherapy for HER2-negative breast cancer benefit from adjuvant treatment with capecitabine, CREATE-X trial data show.

23-06-2017 | Prostate cancer | News | Article

PAM50 classifier defines prostate cancer subtypes

Patients with prostate cancer can be classified into luminal- and basal-like subtypes using the well-known PAM50 algorithm, and the subtypes correlate with clinical outcome, researchers report.

23-06-2017 | Rheumatology | News | Article

Dose reduction of TNF inhibitors a ‘reasonable long-term approach’ for RA patients

The efficacy and safety profiles of disease activity-guided dose reduction of tumor necrosis factor inhibitors are maintained for up to 3 years in patients with rheumatoid arthritis, follow-up results of the DRESS study suggest.

22-06-2017 | Chronic myeloid leukaemia | Main feed | News

Frontline bosutinib ‘an option’ for newly diagnosed CP CML

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

21-06-2017 | Non-small-cell lung cancer | News | Article

Dacomitinib improves EGFR-mutated NSCLC PFS over gefitinib, but at toxicity cost

The ARCHER 1050 investigators believe that their results establish dacomitinib as an addition to the first-line EGFR mutation-positive non-small-cell lung cancer treatment armamentarium, but caution that the associated toxicity needs to be managed.

21-06-2017 | Non-small-cell lung cancer | News | Article

Alectinib ‘new standard of care’ for untreated ALK-positive NSCLC

Compared with crizotinib, alectinib significantly improves progression-free survival in treatment-naïve patients with advanced non-small-cell lung cancer harboring an anaplastic lymphoma kinase rearrangement, shows the ALEX trial.

Beyond the news


medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Interested in paediatric endocrinology?

Visit our dedicated microsite for research news, interviews and in-depth analysis of paediatric endocrinology and growth disorders.


Highlights from the 1st conference of the European Academy of Neurology in Berlin, Germany.

Click through to read research news from the conference.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

image credits